Saur and colleagues perform a high-throughput combinatorial drug screen and identify a synergistic combination between nintedanib and trametinib that sensitizes mesenchymal PDAC to immune checkpoint blockade.
- Chiara Falcomatà
- Stefanie Bärthel
- Dieter Saur